Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Melissa Lumish"'
Autor:
Patrícia M. R. Pereira, Komal Mandleywala, Sébastien Monette, Melissa Lumish, Kathryn M. Tully, Sandeep Surendra Panikar, Mike Cornejo, Audrey Mauguen, Ashwin Ragupathi, Nai C. Keltee, Marissa Mattar, Yelena Y. Janjigian, Jason S. Lewis
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-14 (2022)
Clinical evidences have demonstrated limited efficacy of HER2-targeted therapies in patients with gastric cancer (GC). Here the authors show that survival benefit to anti-HER2 antibody Trastuzumab is reduced in GC patients with high levels of the cav
Externí odkaz:
https://doaj.org/article/38bd18f4fd924b1c8813870074036bf4
Autor:
Justin Jee, Aaron J. Stonestrom, Sean Devlin, Teresa Nguyentran, Beatriz Wills, Varun Narendra, Michael B. Foote, Melissa Lumish, Santosha A. Vardhana, Stephen M. Pastores, Neha Korde, Dhwani Patel, Steven Horwitz, Michael Scordo, Anthony F. Daniyan
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-6 (2021)
Abstract Corticosteroids, anti-CD20 agents, immunotherapies, and cytotoxic chemotherapy are commonly used in the treatment of patients with cancer. It is unclear how these agents affect patients with cancer who are infected with SARS-CoV-2. We retros
Externí odkaz:
https://doaj.org/article/ac5a7ce592fd4888901daa72413e1e59
Autor:
Melissa Lumish, Lorenzo Falchi, Brandon S. Imber, Michael Scordo, Gottfried von Keudell, Erel Joffe
Publikováno v:
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-19 (2021)
Abstract Mature B cell neoplasms, previously indolent non-Hodgkin lymphomas (iNHLs), are a heterogeneous group of malignancies sharing similar disease courses and treatment paradigms. Most patients with iNHL have an excellent prognosis, and in many,
Externí odkaz:
https://doaj.org/article/310ee75c1e3c459aaf149b8457e36129
Autor:
Melissa Lumish, Ryan J. Sullivan, Douglas B. Johnson, Meghan J Mooradian, Daniel Y Wang, Alexandra Coromilas, Tianqi Chen
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
Background Immune-related colitis is a common, often serious complication of immune checkpoint inhibition (ICI). Although endoscopy is not strictly recommended for any grade of diarrhea/colitis, emerging evidence suggests that endoscopic evaluation m
Externí odkaz:
https://doaj.org/article/d3b12f2b32434816bb4e27679556ac4b
Autor:
Ashley Arkema, Robin B. Mendelsohn, Randze Lerie Palmaira, Rosemary Semler, Andrea Cercek, Melissa Lumish, Asha Krishnan, Jill A Weiss, Jeanne Carter, Hadley Maya, Julio Garcia-Aguilar, Zsofia K. Stadler, John P. Mulhall, Anne Casson, Joseph Bacani, Christian J. Nelson
Publikováno v:
Oncologist
The increase in young onset colorectal cancer and the complex care needs of young cancer patients spurred the development of the Center for Young Onset Colorectal Cancer at the Memorial Sloan Kettering Cancer Center. This article describes the lesson
Autor:
Michael Scordo, Lorenzo Falchi, Erel Joffe, Melissa Lumish, Brandon S. Imber, Gottfried von Keudell
Publikováno v:
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-19 (2021)
Journal of Hematology & Oncology
Journal of Hematology & Oncology
Mature B cell neoplasms, previously indolent non-Hodgkin lymphomas (iNHLs), are a heterogeneous group of malignancies sharing similar disease courses and treatment paradigms. Most patients with iNHL have an excellent prognosis, and in many, treatment
Autor:
Eli P. Darnell, Keith D. Lillemoe, Yasmin G. Hernandez-Barco, C. Fernandez-del Castillo, Maximilian Weniger, Brenna Casey, Kumar Krishnan, Cristina R. Ferrone, Thomas J. Wang, Motaz Qadan, Melissa Lumish
Publikováno v:
The American Journal of Surgery. 221:134-140
Objectives Preoperative biliary stenting is required for patients with obstructive jaundice from pancreatic adenocarcinoma who are receiving neoadjuvant chemotherapy. While in most patients this approach results in durable biliary drainage, some pati
Autor:
Molly Maloy, Yonina R. Murciano-Goroff, Aaron J. Stonestrom, Viswatej Avutu, Melissa S. Pessin, Kelly L. Bolton, Rimma Belenkaya, Andriy Derkach, Adam Watson, Justin Jee, Luis A. Diaz, Marina Kerpelev, Melissa Lumish, Beatriz Wills, Chris Fong, John Philip, Yelena Y. Janjigian, Varun Narendra, Jason E. Chan, Michael B. Foote
Publikováno v:
J Clin Oncol
PURPOSECoronavirus-2019 (COVID-19) mortality is higher in patients with cancer than in the general population, yet the cancer-associated risk factors for COVID-19 adverse outcomes are not fully characterized.PATIENTS AND METHODSWe reviewed clinical c
Autor:
J. Joshua Smith, Erin E. Salo-Mullen, Henry Walch, Diana Mandelker, Asha Krishnan, Michael F. Berger, Felix Steinruecke, Neil H. Segal, Gustavo Dos Santos Fernandes, Diane Reidy-Lagunes, Garrett M. Nash, Kimeisha Belanfanti, Leonard B. Saltz, Andrea Cercek, Zsofia K. Stadler, Karuna Ganesh, Anna M. Varghese, Chaitanya Bandlamudi, Mark E. Robson, Melissa Lumish, Jinru Shia, Vijai Joseph, Julio Garcia Aguilar, Nikolaus Schultz, Walid K. Chatila, Robin B. Mendelsohn, P. Paty, Kenneth Offit, Nancy E. Kemeny, Arnold J. Markowitz, Liying Zhang, Louise Catherine Connell, Preethi Srinivasan, Yelena Kemel, Barry S. Taylor, Ozge Birsoy, Jose G. Guillem, David B. Solit, Jesse Galle, Rona Yaeger, Sebastian Mondaca, Efsevia Vakiani, Luis A. Diaz, Anna Maio, Lerie Palmaira, Prince Rainier Tejada, Martin R. Weiser
Publikováno v:
J Natl Cancer Inst
Background The causative factors for the recent increase in early-onset colorectal cancer (EO-CRC) incidence are unknown. We sought to determine if early-onset disease is clinically or genomically distinct from average-onset colorectal cancer (AO-CRC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3723ce25fffa6cdb6d9d05fbf0a82091
https://europepmc.org/articles/PMC8634406/
https://europepmc.org/articles/PMC8634406/
Autor:
Patrícia M. R. Pereira, Komal Mandleywala, Sébastien Monette, Melissa Lumish, Kathryn M. Tully, Sandeep Surendra Panikar, Mike Cornejo, Audrey Mauguen, Ashwin Ragupathi, Nai C. Keltee, Marissa Mattar, Yelena Y. Janjigian, Jason S. Lewis
Publikováno v:
Nature communications. 13(1)
Resistance mechanisms and heterogeneity in HER2-positive gastric cancers (GC) limit Trastuzumab benefit in 32% of patients, and other targeted therapies have failed in clinical trials. Using patient samples, patient-derived xenografts (PDXs), partial